Patients who received molnopiravir within five days of developing symptoms of corona had about half the rate of hospitalization and death compared to patients who received dummy pills.
US drugmaker Merck said Friday that its experimental COVID-19 pills have recently cut hospitalizations and deaths in half in people infected with the coronavirus, and that it will soon ask health officials in the United States and around the world for permission to use them.
And the American “Associated Press” agency said that if the drug is approved, the drug will be the first pill to treat “Covid-19”, which is a potential major step forward in global efforts to control the epidemic. All COVID-19 treatments now authorized in the United States require an intravenous injection.
These at-home pills can keep many patients out of the hospital, easing the workload of overworked healthcare professionals. The drug could also help reduce outbreaks in low-income countries that do not have access to more expensive parenteral treatments.
Merck and its partner, Ridgeback Biotherapeutics, said early results showed that patients who received the drug, called molnupiravir, within five days of developing symptoms of corona had about half the rate of hospitalization and death compared to patients who received dummy pills. .
The study followed 775 adults with mild to moderate infection with the “Covid-19” virus, and they were considered to be more likely to develop serious illnesses due to health problems such as obesity, diabetes or heart disease.
The results were not reviewed by outside experts, which is the usual procedure for examining new medical research.
Of the patients who took molnopiravir, 7.3 percent were hospitalized or died at the end of 30 days, compared to 14.1 percent of those who took the placebo. There were no deaths in the group that received the drugs after that time period compared to eight deaths in the placebo group, according to Merck.
Translated into Arabic: Al-Mayadeen Net